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A report on the 15th Annual Center for Advanced
Biotechnology and Medicine Symposium on structural
genomics in pharmaceutical design, Princeton, USA, 24-25
October 2001.
The  15th  Annual  Center  for  Advanced  Biotechnology  and
Medicine  (CABM)  symposium  on  structural  genomics  in
pharmaceutical design gathered 20 keynote speakers, who
presented  the  most  recent  advances  in  their  structural
genomics projects carried out in both academic institutions
and companies. Here, we will give an overview of some of
the most interesting talks.
High-throughput structural and functional
genomics
After recent successes in genome-sequencing projects, ini-
tiatives in structural genomics aim to understand fully the
biological  role  of  proteins  by  determining  representative
structures for protein families on a genomic scale. Several
investigators, including Stephen Burley (Rockefeller Uni-
versity,  New  York,  USA),  Andrzej  Joachimiak  (Argonne
National  Laboratories,  USA),  Gaetano  Montelione
(Rutgers  University,  Piscataway,  USA  and  CABM),  Wim
Hol  (University  of  Washington,  Seattle,  USA)  and  Sean
Buchanan  (Structural  GenomiX  Inc.,  San  Diego,  USA),
talked  about  their  ongoing  structural  genomic  projects,
most of which are funded by the US National Institutes of
Health (NIH). Automation appears to be a critical factor
for all of the large-scale structure determination projects
discussed here, as protein-structure determinations tradi-
tionally  rely  on  very  labor-intensive  methods  of  gene
cloning,  protein  expression  and  purification,  crystalliza-
tion,  and  structure  determination  and  refinement.
High-throughput protocols are now changing this aspect of
structural biology. 
Joachimiak described an automated protocol for data collec-
tion  and  structure  determination.  Using  the  advanced
photon source (APS), the third-generation synchrotron radi-
ation facility, his group has made great advances in acceler-
ating  progress  in  structure  determination.  The  procedure
they have automated includes: firstly, mounting crystals and
adjusting positions on a beamline; secondly, collecting dif-
fraction  data;  and  thirdly,  structure  determination  and
refinement. By following this protocol, most structures are
solved to high resolution within a very short time period.
Hol described the on-going efforts in his lab towards struc-
ture-based drug-design, with a focus on drugs for diseases
caused by tropical parasites. He also reported the approval
and  funding  of  the  latest  NIH-sponsored  structural
genomics initiative, the Structural Genomics of Pathogenic
Protozoa (SGPP); it will focus on microbial pathogens such
as Trypanosoma brucei and Plasmodium falciparum, which
cause  sleeping  sickness  and  malaria,  respectively.  In  con-
trast to the other structural genomics centers, SGPP selects
potential  targets  on  the  basis  of  function,  which  should
accelerate  the  determination  of  pathogenic  protein  struc-
tures for drug design.
As the central repository of protein structures, the Protein
Data Bank (PDB) [http://www.rcsb.org/pdb/] plays a criti-
cal  role  in  structural  genomics  initiatives.  Helen  Berman
(Rutgers  University,  Piscataway,  USA)  described  on-going
developments at the PDB. The database now includes more
than 16,000 structures, and new entries are being added at a
rate of 50-70 structures per week. About 90% of the new
entries are protein structures, and the average sizes of these
structures  have  gradually  increased  over  time.  One  major2 Genome Biology Vol 3 No 2  Liu et al.
improvement to the database is the automated processing of
submissions  to  ensure  uniformity  in  the  data  files  and
quality of the structures, and a future goal is to allow seam-
less  deposition  of  data  generated  by  structural  genomics
consortia. Berman also mentioned the development of the
Ligand  Depot  database;  it  contains  information  for  about
250,000 small molecules, many of which are found in com-
plexes in PDB structures. Combined with the protein struc-
ture data in PDB, the Ligand Depot will be very useful for
drug-design research in the future. 
Predicting structure and function 
In addition to structure determination, structure prediction
provides alternative ways to look at protein structures and
understand the biological functions of proteins. Jeff Skolnick
(Donald  Danforth  Plant  Science  Center,  St.  Louis,  USA)
described a novel unified method for structural prediction
that combines in one the three most used methods - homol-
ogy  modeling,  threading  and  ab  initio prediction.  The
unified method has the potential to predict active sites from
ab  initio models  of  protein  structure,  using  a  library  of
three-dimensional active-site descriptors. Furthermore, this
method  has  been  extended  to  the  problems  of  multimer
threading (the prediction of protein complexes) and even the
prediction of metabolic pathways. 
Ming-Ming  Zhou  (Mount  Sinai  School  of  Medicine,  New
York,  USA)  detailed  progress  in  designing  ligands  for
bromodomains,  protein  motifs  involved  in  chromatin
re-modeling and binding to acetylated histones. A procedure
for assessing the efficacy of drug binding on a large scale was
presented by Ray Salemme (3-Dimensional Pharmaceuticals
Inc., Exton, USA): the change in melting temperature upon a
ligand binding to a protein target was measured in a high-
throughput screen.
Ronald Levy (Rutgers University, Piscataway, USA) then pre-
sented his laboratory’s recent progress in ab initio tertiary
structure prediction. His work incorporates protein structural
data to guide an all-atom molecular dynamics simulation,
using residual dipolar couplings (a method in nuclear mag-
netic  resonance  structure  determination)  to  generate  a
model of the target protein backbone. A key feature of this
method  involves  searching  the  SCOP  database
[http://scop.mrc-lmb.cam.ac.uk/scop]  with  seven-residue
subsets of the target protein, in order to find a set of dipolar
couplings that most closely match each query fragment. The
predicted backbone is then assembled from candidate proteins
according to their local fit to the dipolar coupling data. Side-
chain placement is accomplished using an energy-minimiza-
tion routine to select optimal angles iteratively from a rotamer
library, until the algorithm converges. Because the prediction
strategy makes use of experimental data to narrow the confor-
mational  search,  there  are  opportunities  to  integrate  this
approach into high-throughput structural genomics efforts.
The role of bioinformatics in structural genomics
In a field involving large quantities of biological data, bioin-
formatics  provides  important  guidance  for  structural
genomics projects, from target selection to data analysis. Two
bioinformatics talks given at the symposium are worthy of
mention. One was by M.G., who described the bioinformatics
studies  being  conducted  by  our  group,  and  in  particular
research on pseudogenes. Although typically there are many
pseudogenes  in  eukaryotic  genomes,  very  little  is  known
about them compared with the functional genes. Research on
pseudogenes investigates the occurrence of genes that have
lost  their  function  through  the  acquisition  of  a  premature
stop  codon.  Combined  with  the  recent  development  of  a
mathematical  model  that  describes  the  process  by  which
genomes evolved to their present state, the research provides
a glimpse into the evolutionary history of the organism.
The second bioinformatics talk was by Cyrus Chothia (MRC
Laboratory of Molecular Biology, Cambridge, UK), who dis-
cussed  several  mechanisms  of  molecular  evolution  with
respect  to  the  observed  repertoire  of  protein  families.  A
protein family is defined as a group of proteins that share a
common  evolutionary  ancestor.  The  recent  sequencing  of
entire genomes enables researchers to identify the members
of these families, and to reveal the biological processes that
contributed to their divergence. Two processes that appear
to be instrumental in protein evolution are gene duplication
and combination. A goal of Chothia’s work is the elucidation
of relationships in sequence and structure between protein
families in a genomic context, which is expected to shed light
on the molecular basis of organismal evolution.
The role of structural genomics in
pharmaceutical drug design
Recent advances in structural genomics not only help us to
understand protein functions but also have a big impact on
the pharmaceutical industry. In the last few years, the use of
protein  structural  information  in  drug  discovery  research
has matured, and it is now used at all levels, ranging from
genomics-derived target identification and selection to the
final design of suitable drug candidates. An especially pow-
erful  methodology  has  arisen  from  the  synergy  of  target
structural information with combinatorial chemistry. 
An excellent example of how structural genomics and combi-
natorial chemistry can be used in rational drug design was
presented  by  Edward  Arnold  (Rutgers  University,  Piscat-
away, USA and CABM), who discussed the optimization of
multiple  factors  in  developing  potent  inhibitors  for  the
reverse  transcriptase  (RT)  enzyme  of  human  immunodefi-
ciency virus (HIV), as potential drugs to prevent the develop-
ment of acquired immunodeficiency syndrome (AIDS). HIV
RT is vital for replication of the virus and is therefore rightly
considered as a primary target for developing drugs. On the
basis of crystal structures of HIV RT and its ligand-boundc
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forms, two primary types of target site were identified: the
dNTP-binding site (used when RT carries out its polymerase
function)  and  the  non-nucleoside  RT-inhibiting  site.  Non-
nucleoside RT-inhibitors (NNRTIs) were found to be espe-
cially  suitable  for  disrupting  HIV  RT  function.
NNRTI-targeted  drugs  should  be  chemically  very  diverse
and should not compete with nucleotide-binding substrates,
while inhibiting RT in nanomolar concentrations. To iden-
tify the most potent NNRTI drugs, Arnold and colleagues
used molecular modeling to calculate the interaction energy
of  a  potential  substrate  bound  at  the  non-nucleoside  RT-
inhibiting  site,  which  consists  of  a  hydrophobic  pocket.  It
turns  out  that  the  lower  energy  conformations  usually
produce the more potent drug. Selected targets are synthe-
sized and then assessed through antiviral screening experi-
ments. This procedure allowed faster design of a number of
powerful  NNRTI  drugs.  The  most  successful  candidates,
such as TMC120 and TMC125, appear to have low toxicity
(in the micromolar range) and high selectivity. Monotherapy
experiments with each of these produce up to 30-fold drop
in the virus population in vitro.
There were many interesting talks in this symposium cover-
ing topics such as structural genomics, bioinformatics, com-
putational  biology,  and  drug  design  methods.  Several
NIH-funded structural genomics pilot projects have shown
promising preliminary results in their first year of funding,
with about 100 structures solved. These projects will do even
better in years to come and will accelerate the pace of struc-
ture  determination,  and  are  sure  to  have  great  impact  on
structural biology research and on drug design in the future.